Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2026)

Arcturus Therapeutics Holdings has reported Net Cash Flow for 9 years, with the latest figure at -$19.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 3.43% year-over-year to -$19.4 million; the trailing twelve-month figure through Mar 2026 stood at -$60.4 million (up 15.42% YoY), and the FY2025 full-year result was -$61.1 million, down 11.17% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$19.4 million, down from -$4.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $154.2 million in Q4 2022, with the low at -$63.9 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$9.4 million across 5 years, with a median of -$20.1 million in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 455.47% — and 2025, when it sank 2867.33%.
• Arcturus Therapeutics Holdings' Net Cash Flow stood at $154.2 million in 2022, then slumped by 113.07% to -$20.2 million in 2023, then surged by 99.26% to -$150000.0 in 2024, then slumped by 2867.33% to -$4.5 million in 2025, then sank by 335.65% to -$19.4 million in 2026.
• The last three Net Cash Flow figures came in at -$19.4 million (Q1 2026), -$4.5 million (Q4 2025), and -$16.1 million (Q3 2025), per Business Quant data.